|Publication Type||Journal Article|
|Year of Publication||2022|
|Authors||Hwang, WL, Jagadeesh, KA, Guo, JA, Hoffman, HI, Yadollahpour, P, Reeves, JW, Mohan, R, Drokhlyansky, E, Van Wittenberghe, N, Ashenberg, O, Farhi, SL, Schapiro, D, Divakar, P, Miller, E, Zollinger, DR, Eng, G, Schenkel, JM, Su, J, Shiau, C, Yu, P, Freed-Pastor, WA, Abbondanza, D, Mehta, A, Gould, J, Lambden, C, Porter, CBM, Tsankov, A, Dionne, D, Waldman, J, Cuoco, MS, Nguyen, L, Delorey, T, Phillips, D, Barth, JL, Kem, M, Rodrigues, C, Ciprani, D, Roldan, J, Zelga, P, Jorgji, V, Chen, JH, Ely, Z, Zhao, D, Fuhrman, K, Fropf, R, Beechem, JM, Loeffler, JS, Ryan, DP, Weekes, CD, Ferrone, CR, Qadan, M, Aryee, MJ, Jain, RK, Neuberg, DS, Wo, JY, Hong, TS, Xavier, R, Aguirre, AJ, Rozenblatt-Rosen, O, Mino-Kenudson, M, Del Castillo, CFernandez-, Liss, AS, Ting, DT, Jacks, T, Regev, A|
|Date Published||2022 Jul 28|
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet inform clinical management or therapeutic development. Here, we construct a high-resolution molecular landscape of the cellular subtypes and spatial communities that compose PDAC using single-nucleus RNA sequencing and whole-transcriptome digital spatial profiling (DSP) of 43 primary PDAC tumor specimens that either received neoadjuvant therapy or were treatment naive. We uncovered recurrent expression programs across malignant cells and fibroblasts, including a newly identified neural-like progenitor malignant cell program that was enriched after chemotherapy and radiotherapy and associated with poor prognosis in independent cohorts. Integrating spatial and cellular profiles revealed three multicellular communities with distinct contributions from malignant, fibroblast and immune subtypes: classical, squamoid-basaloid and treatment enriched. Our refined molecular and cellular taxonomy can provide a framework for stratification in clinical trials and serve as a roadmap for therapeutic targeting of specific cellular phenotypes and multicellular interactions.
|Alternate Journal||Nat Genet|